Bitte warten ...
 

Publikationen

2020

 

Aggressive Lymphome

  • Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines.
    Wirth A, Mikhaeel NG, Pauline Aleman BM, Pinnix CC, Constine LS, Wilmot JP, Ricardi U, Illidge TM, Eich HT, Hoppe BS, Dabaja B, Ng AK, Kirova Y, Berthelsen AK, Dieckmann K, Yahalom J, Specht L.
    Int J Radiat Oncol Biol Phys. 2020 Apr 6:S0360-3016(20)30943-3. DOI: 10.1016/j.ijrobp.2020.03.019. Online ahead of print.PMID: 32272184 Review. No abstract available.

  • Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG.
    Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang RW, Dickinson M, Ng A, Roberts KB, Gao S, Balogh AG, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras JP, Wright C, Kelsey CR, Brady JL, Mikhaeel NG, Hoppe BS, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig JL, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine LS, Eich HT, Wirth A, Hoppe RT.
    Blood. 2020 Mar 25:blood.2019003877. DOI: 10.1182/blood.2019003877. Online ahead of print. PMID: 32211877

  • The Conditional Survival of Patients with Relapsed DLBCL after Auto-Transplant: A Subgroup Analysis of LY.12 and CORAL
    Assouline S, Li S, Gisselbrecht C, Fogarty P, Hay A, Van Den Neste E, Shepherd L, Schmitz N, Baetz T, Keating A, Robinson KS, Seftel M, Stelitano C, Djurfeldt M, Meyer R, Chen B, Crump M
    Blood Advances 2020 (in press)

  • Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosee P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson A-M, von Wangenheim U, Burkard U, Berk A, Schmitz N.
    Investigational New Drugs 2020 (in press)

  • International Prognostic Indices in Diffuse Large B-cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI
    Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert M, Flament J, Flowers C, Shi Q, Schmitz N.
    Blood. 2020 Jun 4;135(23):2041-2048. DOI: 10.1182/blood.2019002729.Blood. 2020.PMID: 32232482

  • A 70% Cut-Off for MYC Protein Expression in Diffuse Large B Cell Lymphoma Identifies a High-Risk Group of Patients
    Ziepert M, Lazzi S, Santi R, Vergoni F, Granai M, Mancini V, Staiger A, Horn H, Löffler M, Pöschel V, Held G, Wulf G, Trümper LH, Schmitz N, Rosenwald A, Sabattini E, Naresh KN, Stein H, Ott G, Leoncini L.Ziepert M, et al.
    Haematologica. 2020 Feb 13:haematol.2019.235556. DOI: 10.3324/haematol.2019.235556. Online ahead of print.Haematologica. 2020. PMID: 32054654

  • Emed Demonstrator Project; German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
    Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Hüttl KS, Glehr G, Klapper W, Szczepanowski M, Richter J, Stein H, Feller AC, Möller P, Hansmann ML, Poeschel V, Held G, Loeffler M, Schmitz N, Trümper L, Pukrop T, Rosenwald A, Ott G, Spang R;
    Leukemia. 2020 Feb;34(2):543-552. DOI: 10.1038/s41375-019-0573-y. Epub 2019 Sep 17. PubMed PMID: 31530861.

     

 

Follikuläres Lymphom

  • Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles.
    Staiger AM, Hoster E, Jurinovic V, Winter S, Leich E, Kalla C, Möller P, Bernd HW, Feller AC, Koch K, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M, Weigert O, Hiddemann W, Herfarth K, Rosenwald A, Engelhard M, Ott G, Horn H.

    Blood. 2020 Jan 16;135(3):181-190. DOI: 10.1182/blood.2019000560 PubMed PMID: 31697802

  • Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients.
    Elsayad K, Reinartz G, Oertel M, Rehn S, Eismann J, Scobioala S, Berssenbrügge H, Eter N, Weishaupt C, Schmidt HH, Friedrichs B, Grünewald I, Hartmann W, Lenz G, Wardelmann E, Willich N, Eich HT.
    Strahlenther Onkol. 2020 Feb;196(2):117-125. DOI: 10.1007/s00066-019-01538-2. Epub 2019 Nov 15. PMID: 31732783

  • HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma.
    Stevens WBC, Bakunina K, Cuijpers M, Chamuleau M, Beeker A, Fijnheer R, Hebart H, Visser HPJ, Doorduijn JK, Linton K, Dreyling M, de Jong D, Kersten MJ.
    Hemasphere. 2020 Jan 3;4(1):e325

 

Indolente Lymphome

  • De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma.
    Oertel M, Elsayad K, Weishaupt C, Steinbrink K, Eich HT.
    Strahlenther Onkol. 2020 Feb;196(2):126-131. DOI: 10.1007/s00066-019-01541-7. Epub 2019 Nov 22. PMID: 31758232 English

  • Marginalzonenlymphom

    • Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. E Zucca, L Arcaini, C Buske, P W Johnson, M Ponzoni, M Raderer, U Ricardi, A Salar, K Stamatopoulos, C Thieblemont, A Wotherspoon, M Ladetto for the ESMO Guidelines Committee. Ann Oncol, 31 (1), 17-29 Jan 2020

  • M. Waldenström

    • Bruton Tyrosine-Kinase Inhibitor on the Rise: Acalabrutinib in Waldenström Macroglobulinemia. Christian Buske. Lancet Haematol, 7 (2), e85-e86 Feb 2020, 7 (2), e85-e86 Feb 2020

 

Mantelzelllymphome

  • Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
    Drandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria G, Ferrante M, Genuardi E, Mantoan B, Villarese P, Cheminant M, Starza ID, Ciabatti E, Bomben R, Jimenez C, Callanan M, Abdo C, Eckert C, Ribrag V, Cortelazzo S, Dreyling M, Hermine O, Delfau-Larue MH, Pott C, Ladetto M, Ferrero S, Macintyre E.
    Hemasphere. 2020 Apr 3;4(2):e347

  • Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11.
    Croci GA, Hoster E, Beà S, Clot G, Enjuanes A, Scott DW, Cabeçadas J, Veloza L, Campo E, Clasen-Linde E, Goswami RS, Helgeland L, Pileri S, Rymkiewicz G, Reinke S, Dreyling M, Klapper W.
    Virchows Arch. 2020 Jan 23. DOI: 10.1007/s00428-020-02750-7. [Epub ahead of print] PubMed PMID: 31975037.

  • Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
    Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH.
    J Clin Oncol. 2020 Jan 20;38(3):248-256. DOI: 10.1200/JCO.19.01294. Epub 2019 Dec 5. PubMed PMID: 31804876.

 

T-Zell-Lymphome

  • Combined total skin radiotherapy and immune checkpoint inhibitors: A promising potential treatment for mycosis fungoides and Sezary syndrome.
    Khaled Elsayad, Rudolf Stadler, Kerstin Steinbrink, Hans Theodor Eich

    J Dtsch Dermatol Ges. 2020 Mar;18(3):193-197. DOI: 10.1111/ddg.14044. Epub 2020 Feb 20. PMID: 32077638 Review

  • Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome.
    Elsayad K, Kroeger K, Greve B, Moustakis C, Assaf C, Stadler R, Lenz G, Weishaupt C, Eich HT.
    Strahlenther Onkol. 2020 Jan;196(1):77-84. DOI: 10.1007/s00066-019-01517-7. Epub 2019 Oct 7. PMID: 31591658 English.

  • Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis.
    Elsayad K, Oertel M, König L, Hüske S, Le Ray E, Meheissen MAM, Elsaid AA, Elfaham E, Debus J, Kirova Y, Herfarth K, Eich HT.
    Cancers (Basel). 2020 Mar 13;12(3):676. DOI: 10.3390/cancers12030676. PMID: 32183106 Free PMC article.

  • Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
    Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, Wilhelm M, Wilhelm C, Pezzutto A, Zijlstra JM, Neste EVD, Lugtenburg PJ, Doorduijn JK, Gelder MV, van Imhoff GW, Zettl F, Braulke F, Nickelsen M, Glass B, Rosenwald A, Gaulard P, Loeffler M, Pfreundschuh M, Schmitz N, Trümper L; ACT-2 study investigators.Wulf GG, et al.
    Leukemia. 2020 May 7. DOI: 10.1038/s41375-020-0838-5. Online ahead of print.Leukemia. 2020.PMID: 32382083

 

Reducing Bureaucracy in Clinical Research: A Call for Action.
Gribben J, Macintyre E, Sonneveld P, Doorduijn J, Gisselbrecht C, Jäger U, Le Gouill S, Rule S, Dreyling M.
Hemasphere. 2020 Feb 26;4(2):e352